Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis.

The article focuses on the expanded access to publicly subsidized lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder (ADHD) in Australia. The topics discussed include the prevalence and incidence of ADHD medicine use among adults in 2021, the impact of the subsidy changes on the dispensing of lisdexamfetamine and other ADHD medicines, and the potential factors driving these changes.